0      0

2022 AABB Annual Meeting

AM22-SN20-L - AM22-SN20-L: Moving Beyond the Label – How the MPHO Unique Identifier Improves Traceability and Enhances Biovigilance (Live)

Oct 2, 2022 3:00pm ‐ Oct 2, 2022 4:00pm

Credits: None available.


Although ISBT 128 has been widely adopted for both blood and cellular therapy, challenges persist in uniquely identifying biologic products throughout their modification events and distribution.
The unique identification of a Medical Product of Human Origin (MPHO) has previously relied upon the combination of multiple identifiers. The lack of standardization of this information within electronic health records (EHRs) or electronic messaging interfaces makes it difficult to maintain product history within and between institutions.
The MPHO Unique Identifier was developed to provide a harmonized approach to capture critical traceability data elements in a single unique identifier for use in data transfer and storage. This data definition provides a standardized format that incorporates multiple fields already present on MPHO labels, including Processing Facility Identification Number, Product Description Code, Donation Identification Number, and Division Identifier, allowing ease in querying.

This session will discuss the use of electronic exchange of information about medical products of human origin from collection through utilization, including a standardized XML message format, and current efforts to harmonize approaches to exchange of information about biologically derived products within HL7 FHIR R5 and the United States Core Data for Interoperability (USCDI). The session will also discuss the MPHO Unique Identifier in detail, along with its successful use in Cellular Therapy, a first for the field.

Learning Objectives:
  • Define the purpose of the MPHO Unique Identifier and develop an understanding of how it is constructed from elements on the ISBT 128 label.
  • Describe how implementation of the MPHO Unique identifier can improve traceability and enhance biovigilance.
  • Explain how the MPHO Unique Identifier can be used in the electronic health record and in electronic messaging and how it enables biologic product/cellular therapy product use in the production environment.
  • Describe options available for the electronic exchange of information about medical products of human origin.




  • Mandy O'Leary, MD, MPH : Bristol Meyers Squibb: Stock Shareholder (self-managed)
  • Karen Moniz, MHA, MT(ASCP)SBB : ICCBBA: Full-time/Part-time Employee
  • Geoffrey Browne : STEMSOFT Software: Full-time/Part-time Employee


Credits: None available.

You must be logged in and own this session in order to post comments.